Suppr超能文献

[前列腺素E1在新生儿心脏畸形中的价值]

[Value of prostaglandin E1 in cardiac malformations in the newborn infant].

作者信息

Sassolas F, Bozio A, Andre M, Jocteur-Monrozier D, Champsaur G, Normand J

出版信息

Pediatrie. 1984 Jun;39(4):245-52.

PMID:6504667
Abstract

Prostaglandin E1 (PGE1) was administered to increase ductus patency in 26 neonates who present a cyanotic heart disease with right ventricular obstruction (1st group, 13 cases) or congestive heart failure with left ventricular outflow obstruction (2nd group, 13 cases). Clinical improvement occurred in all but the oldest infant in the first group. The efficacy of PGE1 is inconstant in the second group, but medical status was very poor before treatment. We could usually reduce the dose of PGE1 but in no case we could stop the drug before surgery. Surgery could be delayed several hours or days to get an hemodynamic and biologic satisfactory condition and even a few weeks until the infants and their pulmonary arteries had grown (1st group). Side effects are common but relatively minor.

摘要

对26例患有右心室梗阻的青紫型心脏病新生儿(第一组,13例)或左心室流出道梗阻的充血性心力衰竭新生儿(第二组,13例)给予前列腺素E1(PGE1)以增加动脉导管通畅。除第一组中年龄最大的婴儿外,所有患儿均有临床改善。PGE1在第二组中的疗效不稳定,但治疗前患儿的病情非常严重。我们通常可以减少PGE1的剂量,但在手术前无一例能够停用该药物。手术可以推迟数小时或数天,以达到血流动力学和生物学上的满意状态,甚至可以推迟数周,直到婴儿及其肺动脉发育成熟(第一组)。副作用很常见,但相对较轻。

相似文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验